Can atorvastatin replace the combination of a fibric acid derivative with a “statin” drug in the treatment of patients with type IIb hypercholesterolemia?

There are no adequate data that evaluate the safety and effectiveness of lowering triglyceride levels in very young children. The authors report a family with two male siblings, 7 and 4 years old, affected by familial hyperchylomicronemia. The oldest was diagnosed at birth during evaluation of jaundice, and the youngest showed asymptomatic hypertriglyceridemia by 6 months of age. Due to high triglyceride levels, Gemfibrozil (a fibric acid derivative) was started at diagnosis. Close clinical followup and laboratory monitoring of these children showed no side effects from the drug, and the risk of acute pancreatitis was significantly reduced.

Download Full-text

Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative

American Journal of Cardiovascular Drugs ◽

10.2165/00129784-200303030-00003 ◽

2003 ◽

Vol 3 (3) ◽

pp. 169-178 ◽

Cited By ~ 17

Author(s):

Michel Farnier

Keyword(s):

Combination Therapy ◽

Acid Derivative ◽

Reductase Inhibitor ◽

Fibric Acid Derivative ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Coa Reductase

Download Full-text

Synergism between a dietary flavonoid and butyric acid derivative in correcting chloride secretory defect in cystic fibrosis pancreatic duct cells

Gastroenterology ◽

10.1016/s0016-5085(01)81676-0 ◽

2001 ◽

Vol 120 (5) ◽

pp. A337-A337

Author(s):

T NGUYEN ◽

S PERRINE ◽

U KIM

Keyword(s):

Cystic Fibrosis ◽

Pancreatic Duct ◽

Acid Derivative ◽

Butyric Acid ◽

Duct Cells ◽

Pancreatic Duct Cells ◽

Dietary Flavonoid

Download Full-text

Moving beyond the “LDL hypothesis”

VASA ◽

10.1024/0301-1526/a000451 ◽

2015 ◽

Vol 44 (5) ◽

pp. 333-340 ◽

Cited By ~ 7

Author(s):

Christian Werner ◽

Ulrich Laufs

Keyword(s):

Ldl Cholesterol ◽

Causal Relation ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Clinical Trial Data ◽

Randomised Clinical Trial ◽

Trial Data ◽

Low Density Lipoprotein Cholesterol ◽

Genetic Studies ◽

Statin Drug

Abstract. Summary: The term “LDL hypothesis” is frequently used to describe the association of low-density lipoprotein cholesterol (LDL-cholesterol, LDL-C) and cardiovascular (CV) events. Recent data from genetic studies prove a causal relation between serum LDL-C and CV events. These data are in agreement with mechanistic molecular studies and epidemiology. New randomised clinical trial data show that LDL-C lowering with statins and a non-statin drug, ezetimibe, reduces CV events. We therefore believe that the “LDL-hypothesis” has been proven; the term appears to be outdated and should be replaced by “LDL causality”.

Download Full-text